Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma
Presented by Amy E. Pierre,(1) MSN, ANP-BC, and Joshua Richter,(2) MD
From (1)Memorial Sloan Kettering Cancer Center, New York, New York; (2)Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, New York
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2020;11(3):306–311 |
© 2020 Harborside™
Amy E. Pierre, MSN, ANP-BC, and Joshua Richter, MD, break down the approved and emerging treatment options for relapsed/refractory multiple myeloma, including mechanisms of action, supporting clinical data, and associated adverse events, and discuss best practices for selecting and sequencing therapy.
For access to the full length article, please sign in